While DNFB cannot be used clinically due to rapid inactivation and sensitizing/tumor-promoting potential following chronic dermal exposure, our data validate CK as a molecular target and justify the development of selective CK inhibitors or SLC6A8 inhibitors such as RGX-202 for future translational studies [24,25]. Here, SLC6A8 is linked to neoplasm.